Richard CPA - Sqz Biotechnologies Chief Officer
Insider
Richard CPA is Chief Officer of Sqz Biotechnologies Co
| Age | 61 |
| Phone | 617 758 8672 |
| Web | https://www.sqzbiotech.com |
Sqz Biotechnologies Management Efficiency
The company has Return on Asset of (0.3332) % which means that on every $100 spent on assets, it lost $0.3332. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.0493) %, meaning that it generated no profit with money invested by stockholders. Sqz Biotechnologies' management efficiency ratios could be used to measure how well Sqz Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities.Sqz Biotechnologies Co has 27.47 M in debt with debt to equity (D/E) ratio of 0.74, which is OK given its current industry classification. Sqz Biotechnologies has a current ratio of 3.79, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Sqz to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Oleg Nodelman | Nuvation Bio | 44 | |
| Arnold Levine | Pmv Pharmaceuticals | 85 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Randi MD | Werewolf Therapeutics | 69 | |
| MD MS | Candel Therapeutics | 53 | |
| Seshu Tyagarajan | Candel Therapeutics | 57 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Jason Amello | Candel Therapeutics | 56 | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| LLM JD | Candel Therapeutics | 64 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Eddie Sullivan | SAB Biotherapeutics | 59 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| David MD | Nuvation Bio | 55 | |
| Gary Hattersley | Nuvation Bio | 58 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Edward MD | Third Harmonic Bio | 52 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Timothy CPA | Werewolf Therapeutics | 67 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
Management Performance
| Return On Equity | -1.05 | |||
| Return On Asset | -0.33 |
Sqz Biotechnologies Leadership Team
Elected by the shareholders, the Sqz Biotechnologies' board of directors comprises two types of representatives: Sqz Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sqz. The board's role is to monitor Sqz Biotechnologies' management team and ensure that shareholders' interests are well served. Sqz Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sqz Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marshelle MD, Chief Officer | ||
| Teri Loxam, Chief Financial Officer | ||
| Howard Bernstein, Chief Scientific Officer | ||
| Marc Schegerin, Independent Director | ||
| Richard CPA, Chief Officer | ||
| Pushkal Garg, Independent Director | ||
| Oliver Rosen, Chief Medical Officer | ||
| Klavs Jensen, Independent Director | ||
| David First, Chief People Officer | ||
| Paul Bolno, Independent Director | ||
| Howard MD, Interim Director | ||
| Armon Sharei, President, Chief Executive Officer, Founder, Interim Chief Financial Officer, Director | ||
| Bernard Coulie, Independent Director | ||
| Amy Schulman, Chairman of the Board | ||
| Marc Elia, Independent Director | ||
| Micah Zajic, Chief Business Officer | ||
| Sapna Srivastava, Independent Director | ||
| Patrick Vink, Independent Director | ||
| Lawrence Knopf, General Counsel | ||
| Ipsita Roymoulik, VP QUALITY |
Sqz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sqz Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.05 | |||
| Return On Asset | -0.33 | |||
| Operating Margin | (3.92) % | |||
| Current Valuation | (6.5 M) | |||
| Shares Outstanding | 29.49 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 66.58 % | |||
| Number Of Shares Shorted | 811.15 K | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 1.24 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Sqz Stock
If you are still planning to invest in Sqz Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sqz Biotechnologies' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |